Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Daniel B. Costa(Beth Israel Deaconess Medical Center), Antonio R. Lucena‐Araujo(Beth Israel Deaconess Medical Center), Ross A. Soo(National University Cancer Institute, Singapore), Michael J. Eck(Harvard University), Norihiro Yamaguchi(Rockefeller University), Geoffrey R. Oxnard(Foundation Medicine (United States)), Maria E. Arcila(Memorial Sloan Kettering Cancer Center), Matthew Meyerson(Broad Institute), Kota Ishioka(Keio University), Mark S. Huberman(Beth Israel Deaconess Medical Center), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Susumu Kobayashi(Beth Israel Deaconess Medical Center), Lecia V. Sequist(Harvard University), Christopher S. Lathan(Harvard University), Jamie E. Chaft(Memorial Sloan Kettering Cancer Center), Eunyoung Park(University of British Columbia), Cai-Hong Yun(Peking University), Wee-Lee Yeo(Beth Israel Deaconess Medical Center), Megan Hanna(Broad Institute), Teresa Morán(Institute of Agrifood Research and Technology), Sohei Nakayama(Beth Israel Deaconess Medical Center), Natasha Sng(Beth Israel Deaconess Medical Center), David Cohen(Beth Israel Deaconess Medical Center)
Cited by 565
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k